Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy
- 10 August 2002
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 13 (12) , 1505-1514
- https://doi.org/10.1089/10430340260185139
Abstract
The only peer-reviewed journal focused on the rapidly moving field of 3D printing and related technologies, providing comprehensive coverage of academic research and industrial and commercial developments that have applications in medicine, education, food, and architecture.This publication has 24 references indexed in Scilit:
- An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene ExpressionMolecular Therapy, 2001
- “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the LungJournal of Virology, 2001
- Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activityGene Therapy, 2001
- Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?Gene Therapy, 2001
- Adenoviral-Mediated Suicide Gene Therapy for Ovarian CancerMolecular Therapy, 2000
- Using a Tropism-Modified Adenoviral Vector to Circumvent Inhibitory Factors in Ascites FluidHuman Gene Therapy, 2000
- Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human TherapyHuman Gene Therapy, 2000
- Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancerCancer Gene Therapy, 2000
- Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patientsGene Therapy, 2000
- Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity.Journal of Clinical Investigation, 1997